TABLE 6.

Effect size and p‐values for the discrete covariates added one at a time to the baseline model with total radical trapping parameter (TRAP) levels as the response.

Variable	Baseline/comparison	Change in mean from baseline (95% CI)	p‐Value
MS type	RRMS/SPMS	−27.4 (−194, 140)	.746
	RRMS/PPMS	−79.6 (−480, 321)	.695
Relapses	No/yes	86.7 (−135, 309)	.440
DMT	No DMT/natalizumab	−200 (−366, −34.4)	.018
	No DMT/azathioprine	−185 (−467, 96.5)	.195
	No DMT/fingolimod	−294 (−550, −37.3)	.025
	No DMT/interferons	−102 (−229, 24.9)	.114
Alcohol	Moderate use/heavy use	−44.8 (−154, 65.0)	.419
Smoking	No/yes	15.6 (−103, 134)	.795

Note: Benjamini–Hochberg method was used to adjust the p‐values at a .05 significance level.

Abbreviations: DMT, disease modifying therapy; PPMS, primary progressive MS; RRMS, relapsing‐remitting MS; SPMS, secondary progressive MS.